2024-01-30 13:04:10 ET
Summary
- GlycoMimetics is developing molecules that target specific carbohydrate groups in the treatment of cancer.
- The company's most advanced project, Uproleselan, has recently shown promising results in a phase 1b/2 study for patients with secondary AML.
- GlycoMimetics has a strong pipeline of projects, but its success hinges on the outcome of a phase 3 trial, which carries significant risk.
Topline Summary and Update
Read the full article on Seeking Alpha
For further details see:
GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real